Akèy › Limfom selil mantèl › Florid
Etid klinik pou Limfom selil mantèl nan Florid
16 etid pou Limfom selil mantèl ap chèche patisipan nan sit nan Florid.
Vil nan Florid
Tèks ofisyèl etid la (Anglè)
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
- Mayo Clinic in Florida, Jacksonville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07285044A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Moffitt Cancer Center, Tampa
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06697184A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Mayo Clinic Jacksonville, Jacksonville
- Mount Sinai Medical Center Braman Comprehensive Cancer Center, Miami
- Tampa General Hospital Cancer Institute, Tampa
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Memorial Cancer Institute, Memorial Healthcare System, Pembroke Pines
- Cleveland Clinic Florida, Weston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06742996Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
- Univ of Miami - Sylvester Comprehensive Cancer Center, Miami
- Moffitt Cancer Center, Tampa
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06553872Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
- University of Miami, Miami
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT06029309Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Jacksonville
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- Mayo Clinic, Jacksonville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT07424833DALY II USA/ MB-CART2019.1 for DLBCL
- Baptist Health Miami Cancer Institute, Miami
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Miami, Miami
- Florida Cancer Specialists, Sarasota
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT05131022The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- ASCLEPES Research Centers, Weeki Wachee
Ap rekriteFaz 1/2
Laj 12 a 95 · Tout sèks · Mizajou Apr 15, 2026 · NCT04329728Study of SGR-1505 in Mature B-Cell Neoplasms
- Napa Research, Pompano Beach
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT05544019B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
- Mayo Clinic in Florida, Jacksonville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT06191887AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Mount Sinai Comprehensive Cancer Center, Miami Beach
- Moffitt Cancer Center, Tampa
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Dec 10, 2025 · NCT05602363SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Jacksonville
- Massive Bio SYNERGY-AI site, Miami
- Massive Bio SYNERGY-AI site, Tampa
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Florida Cancer Specialists, Sarasota
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2025 · NCT05780034Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.